These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 25477091)

  • 41. Copy Number Changes Are Associated with Response to Treatment with Carboplatin, Paclitaxel, and Sorafenib in Melanoma.
    Wilson MA; Zhao F; Khare S; Roszik J; Woodman SE; D'Andrea K; Wubbenhorst B; Rimm DL; Kirkwood JM; Kluger HM; Schuchter LM; Lee SJ; Flaherty KT; Nathanson KL
    Clin Cancer Res; 2016 Jan; 22(2):374-82. PubMed ID: 26307133
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Subretinal fluid associated with MEK and BRAF inhibitors].
    Attia R; Comet A; Stolowy N; Fitoussi R; Michel T; Denis D; David T
    J Fr Ophtalmol; 2022 Nov; 45(9):1091-1092. PubMed ID: 35908992
    [No Abstract]   [Full Text] [Related]  

  • 43. Nivolumab (Opdivo) plus ipilimumab (Yervoy) for metastatic melanoma.
    Med Lett Drugs Ther; 2015 Dec; 57(1483):168. PubMed ID: 26633687
    [No Abstract]   [Full Text] [Related]  

  • 44. Acute kidney injury as a possible immune-related adverse event associated with sustained complete response to BRAF and MEK inhibitors in advanced, V600E-mutated melanoma.
    Di Federico A; Filippini DM; Sperandi F; Ardizzoni A; Melotti B
    Eur J Cancer; 2021 Apr; 147():58-59. PubMed ID: 33618198
    [No Abstract]   [Full Text] [Related]  

  • 45. Targeted therapy of BRAF V600E-mutant histiocytic sarcoma: A case report and review of the literature.
    Branco B; Comont T; Ysebaert L; Picard M; Laurent C; Oberic L
    Eur J Haematol; 2019 Oct; 103(4):444-448. PubMed ID: 31376203
    [No Abstract]   [Full Text] [Related]  

  • 46. Targeted therapies: Drug addiction revealed in BRAF and MEK inhibitor-resistant melanoma cells.
    Sidaway P
    Nat Rev Clin Oncol; 2015 Apr; 12(4):189. PubMed ID: 25687909
    [No Abstract]   [Full Text] [Related]  

  • 47. Combined BRAF and MEK inhibition in BRAF-mutant NSCLC.
    Rivalland G; Mitchell P
    Lancet Oncol; 2016 Jul; 17(7):860-862. PubMed ID: 27283865
    [No Abstract]   [Full Text] [Related]  

  • 48. BRAF Inhibitors and IFNα: Plus, Minus, or Indeterminate?
    Davar D; Fuchs SY; Kirkwood JM
    J Natl Cancer Inst; 2016 Jul; 108(7):. PubMed ID: 26851801
    [No Abstract]   [Full Text] [Related]  

  • 49. Targeted treatment of papillary craniopharyngiomas harboring BRAF V600E mutations.
    Juratli TA; Jones PS; Wang N; Subramanian M; Aylwin SJB; Odia Y; Rostami E; Gudjonsson O; Shaw BL; Cahill DP; Galanis E; Barker FG; Santagata S; Brastianos PK
    Cancer; 2019 Sep; 125(17):2910-2914. PubMed ID: 31314136
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Ansprechen eines metastasierten akrolentiginösen Melanoms mit Exon-11-BRAF-G469A-Mutation auf BRAF/MEK-Inhibition.
    Julius K; Kromer C; Schnabel V; Vlahova L; Kitz J; Schön MP; Sahlmann CO; Kretschmer L
    J Dtsch Dermatol Ges; 2022 Apr; 20(4):527-529. PubMed ID: 35446501
    [No Abstract]   [Full Text] [Related]  

  • 51. Molecular drivers of cellular metabolic reprogramming in melanoma.
    Abildgaard C; Guldberg P
    Trends Mol Med; 2015 Mar; 21(3):164-71. PubMed ID: 25618774
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Acute motor and sensory axonal neuropathy related to treatment with MEK inhibitors in a patient with advanced melanoma.
    Taha T; Tzuk-Shina T; Forschner I; Bar-Sela G
    Melanoma Res; 2017 Dec; 27(6):632-634. PubMed ID: 28872488
    [TBL] [Abstract][Full Text] [Related]  

  • 53. BRAF Mutations: The Discovery of Allele- and Lineage-Specific Differences.
    Hanrahan AJ; Solit DB
    Cancer Res; 2022 Jan; 82(1):12-14. PubMed ID: 34983783
    [TBL] [Abstract][Full Text] [Related]  

  • 54. BRAF-MEK inhibition in melanoma brain metastases: a new hope.
    Forsyth PA; Smalley KSM; Sondak VK
    Lancet Oncol; 2017 Jul; 18(7):836-837. PubMed ID: 28677560
    [No Abstract]   [Full Text] [Related]  

  • 55. Case of inflammatory arthritis induced by encorafenib and binimetinib in a patient with melanoma.
    Matsudate Y
    J Dermatol; 2020 Sep; 47(9):e328-e329. PubMed ID: 32613671
    [No Abstract]   [Full Text] [Related]  

  • 56. BRAF mutations in Erdheim-Chester disease.
    Emile JF; Charlotte F; Amoura Z; Haroche J
    J Clin Oncol; 2013 Jan; 31(3):398. PubMed ID: 23248255
    [No Abstract]   [Full Text] [Related]  

  • 57. Rescue surgery in a patient with metastatic melanoma and BRAF V600E mutation.
    de Miguel M; Jimeno J; Vidal J; Segura S; Lorente L
    Cir Esp (Engl Ed); 2018 Dec; 96(10):665-666. PubMed ID: 29983163
    [No Abstract]   [Full Text] [Related]  

  • 58. Small molecules against B-RAF (BRAF) Val600Glu (V600E) single mutation.
    Zaharie F; Cojocneanu-Petric R; Muresan M; Frinc I; Dima D; Petrushev B; Tanase A; Berce C; Chitic M; Berindan-Neagoe I; Pileczki V; Irimie A; Tomuleasa C
    Int J Nanomedicine; 2015; 10():4897-9. PubMed ID: 26261416
    [No Abstract]   [Full Text] [Related]  

  • 59. Triple Therapy to Outwit the
    Zhang C; Bollag G
    Cancer Discov; 2021 Jul; 11(7):1620-1622. PubMed ID: 34284995
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The Aged Microenvironment of Melanoma Feeds Escape from Targeted Therapy.
    Montal ED; White RM
    Cancer Discov; 2020 Sep; 10(9):1255-1257. PubMed ID: 32873617
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.